Epix and Dyax sign contrast deal
The development of new nuclear medicine and MRI contrast agents is the focus of an alliance signed last month between Epix Medical and Dyax. The two Cambridge, MA, companies have agreed to join forces to spur development of agents to diagnose pulmonary
The development of new nuclear medicine and MRI contrast agents is the focus of an alliance signed last month between Epix Medical and Dyax. The two Cambridge, MA, companies have agreed to join forces to spur development of agents to diagnose pulmonary emboli and deep-vein thrombosis.
Epix is developing MRI agents like its MS-325 cardiovascular imaging agent (SCAN 2/19/97), while Dyax has developed a novel process for identifying proteins that could form the basis for new imaging agents (SCAN 11/20/96). Under the terms of the agreement, the companies will use Dyax's phage-display technology to identify peptides that bind to pulmonary emboli and deep-vein thrombosis.
Epix will fund the phage-display screening program and will provide expertise for developing MRI-specific imaging agents, while Dyax will assume responsibility for developing nuclear medicine agents. Both companies will receive royalties for products resulting from the collaboration.
In other Epix news, the company has begun phase II clinical trials of MS-325. The trials will investigate the safety and preliminary efficacy of the MRI agent for the evaluation of peripheral vascular disease in the carotid, iliac, and femoral arteries. Epix has licensed the agent to Mallinckrodt of St. Louis.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
